OSTXHealthcare · BiotechnologyThe 4 Wall Street analysts covering OS Therapies, Inc. hold a median 12-month price target of $7.5 — +383.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 6 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores OS Therapies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (82): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OSTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +383.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 July 2026 | Roth Capital | Initiates | Buy | — |
| 19 May 2026 | Lake Street | Maintains | Buy | — |
| 30 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 9 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 15 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 9 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 5 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Nov 2025 | Lake Street | Maintains | Buy | — |
| 17 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 30 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 2 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 20 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OSTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, OS Therapies, Inc. returned −24.0% against +17.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 97% of US stocks
Cheaper than 72% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 99% of US stocks
Higher than 1% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OS Therapies, Inc. has a market value of $74.9M and an enterprise value of $74.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$39.4M.
Free cash flow in the twelve months to 30 June 2026: −$18.5M.
Trailing P/E: −1.7×; forward P/E: 4.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
OS Therapies, Inc. employs 4 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own OS Therapies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
OS Therapies announced a statistically significant three-year overall survival benefit for patients treated with OST-HER2 in its Phase 2b trial.
Why it matters — The reported survival result is relevant to OSTX watchers tracking clinical-trial outcomes for OST-HER2.
OS Therapies reported a statistically significant three-year overall survival rate of 72.7% for Herlystic-treated patients in its Phase 2b pulmonary metastatic osteosarcoma trial, compared with 45.8% for a comparable combined historical control (p=0.0006). The company is preparing submissions for early market access in the U.S., U.K., Europe and Australia.
Why it matters — The survival findings and planned early market access submissions are relevant developments for OSTX watchers tracking the therapy’s clinical and regulatory progress.
OS Therapies announced the appointment of Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer. The two new executives will focus on preparations for the U.S., U.K., and European commercial launch of the Company's lead product candidate, Herlystic (OST-HER2).
Why it matters — The appointments signal that OS Therapies is strengthening its executive team ahead of commercial activities for its lead candidate in multiple markets.
OS Therapies announced that the World Health Organization has approved "Herlystic" as the brand name for its investigational immunotherapy OST-HER2. The nonproprietary name for the ingredients, daznelimgene lisbac, had been previously approved by the WHO.
Why it matters — A WHO-approved brand name is a formal regulatory milestone that advances the commercial and regulatory development of OST-HER2, a key candidate in OS Therapies' pipeline.
OS Therapies completed an FDA Type C Statistical Methods Meeting, resulting in alignment on an amended Phase 3 study design for OST-HER2, and provided an update on global regulatory coordination. The UK MHRA, under Project Orbis, will serve as the lead regulatory agency to drive early market access, with a Conditional Marketing Authorisation Application submission planned in the coming weeks and Phase 3 trial initiation expected in mid Q4 2026. A patient previously reported lost to follow-up was confirmed alive.
Why it matters — This update signals regulatory alignment and progress for OST-HER2's Phase 3 development and early market access pathway, making it a key development for OS Therapies watchers.
The 4 Wall Street analysts covering OS Therapies, Inc. have a median 12-month price target of $7.5, with estimates ranging from $6 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering OS Therapies, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OS Therapies, Inc. 38 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, OS Therapies, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (82 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +383.9% from the last close, and Ticker Nerd's factor model ranks OS Therapies, Inc. 38 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering OS Therapies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $13 over the next 12 months.
OS Therapies, Inc. returned -24.0% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
OS Therapies Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for osteosarcoma and other solid tumors.
The most recent item we track (Benzinga, 6 Oct 2026): "OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment". OS Therapies announced a statistically significant three-year overall survival benefit for patients treated with OST-HER2 in its Phase 2b trial.
OS Therapies Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for osteosarcoma and other solid tumors. The company’s current work centers on oncology programs that aim to harness the immune system against cancers expressing HER2, including its lead immunotherapy candidate OST-HER2. OS Therapies also advances an antibody-drug conjugate platform designed to support targeted cancer therapy development. Its product pipeline is directed toward high-unmet-need cancers, particularly rare bone cancers and other HER2-related solid tumors. Based in Grasonville, Maryland, OS Therapies Inc. operates within the biotechnology sector as a development-stage company focused on investigational cancer treatments and platform technologies for future clinical use.
CEO Mr. Paul A. Romness M.P.H. · 4 employees · United States · https://ostherapies.com
